Atlanta, GA –June 30th, 2015– Personalized medicine and genomics company AKESOgen today announced that its CLIA-compliant laboratory has received the Florida Clinical Laboratory License, which will allow the company to perform its oncology testing services on patient samples from the state of Florida.
The Georgia based company said in a statement that it believes its cytogenomics tests for a wide spectrum of solid and liquid tumors will be of particular benefit to the state –as the test is offered as a complement to NGS clinical oncology testing.
“This endorsement by the State of Florida for AKESOgen provide our comprehensive oncology tests and services gives AKESOgen access to the single largest US oncology diagnostics market, and will help accelerate our commercial growth in this sector.” said Mark Bouzyk, CSO of AKESOgen.
About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.
Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or email@example.comShare this